22.418 articles found

USE OF GABAA INVERSE AGONISTS IN COMBINATION WITH NICOTINE RECEPTOR PARTIAL AGONISTS, ESTROGEN, SELECTIVE ESTROGEN MODULATORS, OR VITAMIN E FOR THE TREATMENT OF COGNITIVE DISORDERS

VILLALOBOS ANABELLA.

· 2003-08-25

[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.

Kumar A, Mann S, Sossi V, Ruth TJ, Stoessl AJ, Schulzer M, Lee CS.

Brain · 2003-08-22

DOI: 10.1093/brain/awg270PMID: 12937076

Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma.

Delgado M, Ganea D.

FASEB J · 2003-08-15

DOI: 10.1096/fj.02-1029fjePMID: 12923064

Aminoadamantane derivatives as therapeutic agents

WANG YUQIANG, YE WENQING, LARRICK JAMES W, STAMLER JONATHAN S, LIPTON STUART A.

· 2003-08-04

Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa.

Schaafsma JD, Giladi N, Balash Y, Bartels AL, Gurevich T, Hausdorff JM.

J Neurol Sci · 2003-08-01

DOI: 10.1016/s0022-510x(03)00104-7PMID: 12809998

Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?

Fiala KH, Whetteckey J, Manyam BV.

Parkinsonism Relat Disord · 2003-08-01

DOI: 10.1016/s1353-8020(03)00040-3PMID: 12853231

Recent developments in the pharmacological treatment of Parkinson's disease.

Tuite P, Riss J.

Expert Opin Investig Drugs · 2003-08-01

DOI: 10.1517/13543784.12.8.1335PMID: 12882620

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM.

Mov Disord · 2003-08-01

DOI: 10.1002/mds.10464PMID: 12889076

Cabergoline versus levodopa monotherapy: a decision analysis.

Smala AM, Spottke EA, Machat O, Siebert U, Meyer D, Köhne-Volland R, Reuther M, DuChane J, Oertel WH, Berger KB, Dodel RC.

Mov Disord · 2003-08-01

DOI: 10.1002/mds.10465PMID: 12889079

Prevalence, etiology, and treatment of depression in Parkinson's disease.

McDonald WM, Richard IH, DeLong MR.

Biol Psychiatry · 2003-08-01

DOI: 10.1016/s0006-3223(03)00530-4PMID: 12893111

Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.

Blandini F, Nappi G, Fancellu R, Mangiagalli A, Samuele A, Riboldazzi G, Calandrella D, Pacchetti C, Bono G, Martignoni E.

J Neural Transm (Vienna) · 2003-08-01

DOI: 10.1007/s00702-003-0004-zPMID: 12898346

The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.

Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D.

Pharmacol Toxicol · 2003-08-01

DOI: 10.1034/j.1600-0773.2003.930202.xPMID: 12899667